发表机构
University of Bern; University of Napoli Federico II（伯尔尼大学; 那不勒斯费德里科二世大学）
机构由 AI 辅助整理，请以论文原文为准。AI 中文总结
本研究利用伯尔尼医用回旋加速器作为临床前质子治疗研究平台，通过体外细胞实验证实质子照射比X射线具有更强的细胞杀伤效应，为建立综合放射生物学设施奠定基础。
AI 中文摘要
伯尔尼大学高能物理实验室和解剖学研究所正在伯尔尼大学医院（Inselspital）建立一座临床前质子治疗研究设施。该设施以伯尔尼医用回旋加速器为核心，这是一台18 MeV的紧凑型回旋加速器，设计用于微安级束流电流以进行放射性同位素生产。伯尔尼医用回旋加速器可被改造为一个高度可及且可定制的临床前质子治疗研究平台，支持超高剂量率（FLASH）放疗和空间分割放射治疗等先进模式。人角质形成细胞（HaCaT）和小鼠黑色素瘤（B16-F10）细胞系在常规剂量率下接受8.14(29) MeV质子照射，以及接受0至8 Gy剂量范围内的225 kV X射线照射。使用线性二次模型分析克隆形成存活实验，并通过比较0.1存活率时所需的质子和X射线剂量得出相对生物有效性值。质子照射产生的存活曲线比X射线更陡峭，表明其细胞毒性更高。B16-F10细胞最为敏感，在0.1存活率时相对生物有效性为1.34，而HaCaT细胞在0.1存活率时相对生物有效性为1.21。这些结果证实了质子在细胞杀伤方面的增强效应，并证明伯尔尼医用回旋加速器为放射生物学研究提供了可靠平台。建立体外质子照射能力标志着向在伯尔尼开发综合性临床前放射生物学研究设施迈出的关键一步。正在进行的升级将进一步优化剂量测定和质子传输，为未来的FLASH和质子空间分割放射治疗研究铺平道路。
英文摘要
The Laboratory for High Energy Physics and the Institute of Anatomy at the University of Bern are establishing a pre-clinical proton therapy research facility at the Bern University Hospital (Inselspital). The facility centers on the Bern Medical Cyclotron, an 18 MeV compact cyclotron designed for microampere-range beam currents for radioisotope production. The Bern Medical Cyclotron can be adapted as a highly accessible and customizable platform for pre-clinical proton therapy research, enabling advanced modalities such as ultra-high dose rate (FLASH) radiotherapy and spatially fractionated radiation therapy. Human keratinocytes (HaCaT) and mouse melanoma (B16-F10) cell lines were irradiated with 8.14(29) MeV protons at conventional dose rates and with 225 kV X-rays at doses from 0 to 8 Gy. Clonogenic survival assays were analyzed using the linear-quadratic model, and relative biological effectiveness values were derived by comparing the proton and X-ray doses required for 0.1 survival. Proton irradiation yielded steeper survival curves than X-rays, indicating higher cytotoxicity. B16-F10 cells were most sensitive, with a relative biological effectiveness of 1.34 at 0.1 survival, while HaCaT cells showed a relative biological effectiveness of 1.21. These results confirm enhanced proton effectiveness in cell killing and demonstrate that the Bern Medical Cyclotron provides a reliable platform for radiobiological studies. Establishing in vitro proton irradiation capability marks a key milestone toward developing a comprehensive pre-clinical radiobiology research facility in Bern. Ongoing upgrades will further refine dosimetry and proton delivery, paving the way for future FLASH and proton spatially fractionated radiation therapy studies.
